#India #Mumbai #pharmaceuticals #Piramal Pharma

Piramal Pharma Limited Reports Fourth Quarter and Full Year Results for FY 2026

On April 30, 2026, Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), a distinguished player in the pharmaceutical, health, and wellness industry, published its financial results for the fourth quarter and full fiscal year ended March 31, 2026. The firm reflects a year intertwined with challenges yet shows signs of resilience and growth across various segments.

Key Financial Highlights

The consolidated financial report for the fourth quarter (Q4 FY26) presents the following metrics:

• - Revenue from Ongoing Operations: ₹2,752 Crore, showing a slight decrease of 0% compared to ₹2,754 Crore in Q4 FY25. For the full fiscal year, the revenue hit ₹8,869 Crore, down 3% from ₹9,151 Crore in the previous year.

- CDMO Segment: Revenue dropped to ₹1,708 Crore, reflecting a 4% decrease year over year.
- CHG Segment: Managed to achieve a 7% increase in revenue, totaling ₹755 Crore in Q4 FY26.
- PCH Segment: Saw significant growth of 17% with revenue of ₹320 Crore in Q4.

With an EBITDA of ₹507 Crore in Q4 FY26—down 16% from the previous year's ₹603 Crore—the EBITDA margin also saw a decline from 22% to 18%. Further adjustments due to extraordinary items led to a net profit after extraordinary items showing a loss of ₹9 Crore, a stark contrast to a profit of ₹154 Crore in the same quarter last year.

Nandini Piramal, Chairperson of Piramal Pharma Limited, described the year as a transitional one, marked by external disruptions alongside specific business factors. She noted, "Despite these challenges, we have ended the year on a strong note, demonstrating significant momentum in all our business areas."

Operational Highlights

The quarterly report reflects growth strategies are taking shape, particularly in the following areas:

• - Contract Development and Manufacturing Organization (CDMO): A solid rebound characterized the second half of FY26, primarily due to improved biopharma financing in the US, which surged by 75%. The acquisition of new projects also contributed to a vibrant pipeline.
• - Complex Hospital Generics (CHG): The completion of the Kenalog® acquisition not only broadened PPL’s CHG portfolio but also opened new revenue streams with minimal additional costs. Leading 47% of the market share in inhalation anesthesia reflects PPL’s notable strength in this segment.
• - Piramal Consumer Healthcare (PCH): Power Brands like Little's and Lacto Calamine experienced a robust growth rate of 24%, underpinning the revenue mix positively. Notably, the E-Commerce segment surged by 48% year-on-year, contributing around 27% to overall sales in PCH.

Future Directions

Looking ahead, the company is poised for growth alongside a clearer focus on EBITDA improvements and profit after tax for the upcoming fiscal year. Highlights include continued investments in capacity-building in key global locations, with projected capital expenditures reaching $94 million in FY26. Moreover, PPL aims to maintain its competitive edge by optimizing operations across its three business segments.

This annual report underlines the company's adeptness at navigating turbulent market conditions while capitalizing on growth opportunities across its diverse product lines. Proactive engagement with clients and stakeholder transparency has positioned Piramal Pharma Limited as a reputed name in the pharmaceutical landscape.

For detailed insights and discussions, Piramal Pharma is expected to host a teleconference on April 29, 2026, aiming to engage investors and analysts regarding these results in depth.

As Piramal Pharma Limited further establishes its presence in various markets, its strategies continue to reflect a commitment to enhancing healthcare accessibility while promising a vision for sustainable growth in coming years.